{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:01:06Z","timestamp":1790632866670,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015822","name":"Fondazione Roma","doi-asserted-by":"publisher","award":["NCDS-2013-00000308"],"award-info":[{"award-number":["NCDS-2013-00000308"]}],"id":[{"id":"10.13039\/501100015822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2010-2313809"],"award-info":[{"award-number":["RF-2010-2313809"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vph.2020.106676","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T11:37:10Z","timestamp":1585222630000},"page":"106676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Increased fractalkine and vascular dysfunction in obesity and in type 2 diabetes. Effects of oral antidiabetic treatment"],"prefix":"10.1016","volume":"128-129","author":[{"given":"Francesca","family":"Schinzari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfredi","family":"Tesauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Campia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Cardillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.vph.2020.106676_bb0005","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0735-1097(03)00994-X","article-title":"The clinical implications of endothelial dysfunction","volume":"42","author":"Widlansky","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.vph.2020.106676_bb0010","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/01.CIR.0000057548.68243.42","article-title":"Decreased atherosclerotic lesion formation in CX3CR1\/apolipoprotein E double knockout mice","volume":"107","author":"Combadiere","year":"2003","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.vph.2020.106676_bb0015","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1161\/CIRCULATIONAHA.107.743872","article-title":"Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2\u2212\/\u2212 mice: evidence for independent chemokine functions in atherogenesis","volume":"117","author":"Saederup","year":"2008","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.vph.2020.106676_bb0020","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1161\/ATVBAHA.112.300930","article-title":"Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice","volume":"33","author":"Poupel","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.vph.2020.106676_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10557-009-6210-7","article-title":"Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice","volume":"24","author":"Liu","year":"2010","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.vph.2020.106676_bb0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1253\/circj.CJ-09-0484","article-title":"Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris","volume":"74","author":"Ikejima","year":"2010","journal-title":"Circ. J."},{"issue":"1","key":"10.1016\/j.vph.2020.106676_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2009.03.044","article-title":"Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis","volume":"207","author":"Apostolakis","year":"2009","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.vph.2020.106676_bb0040","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2337\/db10-0956","article-title":"Fractalkine is a novel human adipochemokine associated with type 2 diabetes","volume":"60","author":"Shah","year":"2011","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.vph.2020.106676_bb0045","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2013.03.001","article-title":"The fractalkine\/CX3CR1 system regulates beta cell function and insulin secretion","volume":"153","author":"Lee","year":"2013","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.vph.2020.106676_bb0050","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1172\/JCI94330","article-title":"Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function","volume":"128","author":"Riopel","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.vph.2020.106676_bb0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.vph.2020.106676_bb0060","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.vph.2020.106676_bb0065","doi-asserted-by":"crossref","first-page":"E787","DOI":"10.1152\/ajpendo.00278.2015","article-title":"Vasodilator responses and endothelin-dependent vasoconstriction in metabolically healthy obesity and the metabolic syndrome","volume":"309","author":"Schinzari","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"7","key":"10.1016\/j.vph.2020.106676_bb0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.vph.2020.106676_bb0075","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jacc.2017.07.763","article-title":"Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women","volume":"70","author":"Caleyachetty","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.vph.2020.106676_bb0080","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-8587(18)30137-2","article-title":"Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses\u2019 Health Study): 30 year follow-up from a prospective cohort study","volume":"6","author":"Eckel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.vph.2020.106676_bb0085","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/db11-0239","article-title":"Fractalkine: a cellular link between adipose tissue inflammation and vascular pathologies","volume":"60","author":"Cefalu","year":"2011","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.vph.2020.106676_bb0090","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1053\/meta.2002.33354","article-title":"High serum concentrations of soluble E-selectin correlate with obesity but not fat distribution in patients with type 2 diabetes mellitus","volume":"51","author":"Matsumoto","year":"2002","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.vph.2020.106676_bb0095","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/sj.ijo.0803259","article-title":"Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters","volume":"30","author":"Kim","year":"2006","journal-title":"Int. J. Obes."},{"issue":"1","key":"10.1016\/j.vph.2020.106676_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2012.06.018","article-title":"Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes","volume":"60","author":"Panee","year":"2012","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.vph.2020.106676_bb0105","doi-asserted-by":"crossref","first-page":"E2034","DOI":"10.1210\/jc.2011-1050","article-title":"Circulating concentrations of monocyte chemoattractant protein-1, plasminogen activator inhibitor-1, and soluble leukocyte adhesion molecule-1 in overweight\/obese men and women consuming fructose- or glucose-sweetened beverages for 10 weeks","volume":"96","author":"Cox","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.vph.2020.106676_bb0110","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.metabol.2013.02.001","article-title":"Elevated plasma fractalkine levels are associated with higher levels of IL-6, Apo-B, LDL-C and insulin, but not with body composition in a large female twin sample","volume":"62","author":"Franco","year":"2013","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.vph.2020.106676_bb0115","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1161\/ATVBAHA.110.211342","article-title":"High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo","volume":"30","author":"Bursill","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.vph.2020.106676_bb0120","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1096\/fj.12-212753","article-title":"High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells","volume":"27","author":"van der Vorst","year":"2013","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.vph.2020.106676_bb0125","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cvr\/cvu115","article-title":"Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1\/CX3CR1 axis","volume":"103","author":"Martinez-Hervas","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"10","key":"10.1016\/j.vph.2020.106676_bb0130","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00125-013-2976-z","article-title":"Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study","volume":"56","author":"Tripathy","year":"2013","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.vph.2020.106676_bb0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1677\/JME-09-0090","article-title":"Rosiglitazone activation of PPARgamma suppresses fractalkine signaling","volume":"44","author":"Wan","year":"2010","journal-title":"J. Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.vph.2020.106676_bb0140","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.bbrc.2009.12.089","article-title":"Similar effects of resistin and high glucose on P-selectin and fractalkine expression and monocyte adhesion in human endothelial cells","volume":"391","author":"Manduteanu","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.vph.2020.106676_bb0145","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1053\/j.ajkd.2015.01.021","article-title":"Serum Fractalkine (CX3CL1) and cardiovascular outcomes and diabetes: findings from the chronic renal insufficiency cohort (CRIC) study","volume":"66","author":"Shah","year":"2015","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.vph.2020.106676_bb0150","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0735-1097(01)01129-9","article-title":"Improved endothelial function with metformin in type 2 diabetes mellitus","volume":"37","author":"Mather","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.vph.2020.106676_bb0155","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2337\/diacare.27.6.1349","article-title":"Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes","volume":"27","author":"Natali","year":"2004","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.vph.2020.106676_bb0160","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2337\/diacare.24.4.738","article-title":"Sulfonylurea treatment of type 2 diabetic patients does not reduce the vasodilator response to ischemia","volume":"24","author":"Spallarossa","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.vph.2020.106676_bb0165","doi-asserted-by":"crossref","unstructured":"E.J. Abbink, P. Pickkers, A. Jansen van Rosendaal, J.A. Lutterman, C.J. Tack, F.G. Russel, P. Smits, Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients, Diabet Med 19(2) (2002) 136\u201343.","DOI":"10.1046\/j.1464-5491.2002.00663.x"},{"issue":"2","key":"10.1016\/j.vph.2020.106676_bb0170","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2337\/diacare.27.2.484","article-title":"In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control","volume":"27","author":"Pistrosch","year":"2004","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.vph.2020.106676_bb0175","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/01.fjc.0000187176.13403.05","article-title":"Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes","volume":"46","author":"Martens","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"2","key":"10.1016\/j.vph.2020.106676_bb0180","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/meta.2003.50023","article-title":"The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial","volume":"52","author":"Caballero","year":"2003","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.vph.2020.106676_bb0185","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2006-05-020875","article-title":"Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo","volume":"109","author":"Chandrasekharan","year":"2007","journal-title":"Blood"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189119302939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189119302939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:18:20Z","timestamp":1761527900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189119302939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":37,"alternative-id":["S1537189119302939"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2020.106676","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased fractalkine and vascular dysfunction in obesity and in type 2 diabetes. Effects of oral antidiabetic treatment","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2020.106676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106676"}}